Recommendations for follow up in castration resistant prostate cancer

被引:0
|
作者
Vazquez-Alonso, Fernando [1 ]
Puche-Sanz, Ignacio [1 ]
Manuel Cozar-Olmo, Jose [1 ]
机构
[1] Hosp Univ Virgen Nieves, UGC Urol, Avda Fuerzas Armadas 2, Granada 18014, Spain
来源
ARCHIVOS ESPANOLES DE UROLOGIA | 2018年 / 71卷 / 08期
关键词
Prostate cancer; Diagnosis; Follow up; Castration resistance; Metastases; CLINICAL-TRIALS; FREE SURVIVAL; PHASE-II; ENZALUTAMIDE; ABIRATERONE; GUIDELINES; DISEASE; DESIGN; PET/CT; MEN;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES: There is no broad consensus about what diagnostic tests use for CRPC follow up as well as their frequency. Our objective is to review and analyze the most important CRPC follow up patterns described in the literature to date. METHODS: We performed a critical analysis of the recommendations for follow up most universally employed (PCWG3, RADAR, St Gallen consensus, NCCN guidelines, EAU guidelines) RESULTS: CT scan and bone scan are the routine recommended diagnostic tests, in front of other techniques such as PET/CT or MRI, that may improve the diagnostic efficacy but they have the problem of availability and lack of internal validity for follow up. CONCLUSIONS: Follow up is different for non metastatic and metastatic CRPC. For nm CRPC, it is recommended to perform monitoring that includes PSA and imaging tests, without consensus about periodicity. For mCRPC, it is recammendable to do follow up with periodic PSA and imaging tests, since it is possible to have radiological progression without PSA progression.
引用
收藏
页码:735 / 742
页数:8
相关论文
共 50 条
  • [31] Abiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer
    Al-Samsam, Sofya
    Bartos, Jiri
    Samal, Vladimir
    Dvorak, Josef
    Kolarova, Hana
    Richter, Igor
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2024, 29 (01) : 1 - 9
  • [32] Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer
    Merseburger, Axel S.
    Bellmunt, Joaquim
    Jenkins, Cheryl
    Parker, Chris
    Fitzpatrick, John M.
    ONCOLOGIST, 2013, 18 (05) : 558 - 567
  • [33] Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
    Rodriguez-Vida, Alejo
    Galazi, Myria
    Rudman, Sarah
    Chowdhury, Simon
    Sternberg, Cora N.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3325 - 3339
  • [34] Emerging therapies targeting castration-resistant prostate cancer
    Gkialas, Ioarmis K.
    Fragkoulis, Charalampos
    JOURNAL OF BUON, 2015, 20 (06): : 1389 - 1396
  • [35] Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancer
    Gschwend, Juergen E
    Miller, Kurt
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (01): : 41 - 49
  • [36] Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations
    Oudard, Stephane
    Timsit, Marc-Olivier
    Maillet, Denis
    Mouillet, Guillaume
    Campedel, Luca
    Colomba, Emeline
    Dourthe, Louis Marie
    Eymard, Jean-Christophe
    Gobert, Aurelien
    Jamet, Claire
    Joly, Charlotte
    Serrate, Camille
    Ploussard, Guillaume
    BULLETIN DU CANCER, 2025, 112 (01) : 61 - 81
  • [37] ?Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil?
    Jardim, Denis L.
    Silva, Adriano Goncalves e
    Pompeo, Alexandre Saad Fere Lima
    Sarkis, Alvaro Sadek
    Cardoso, Ana Paula Garcia
    Sasse, Andre Deeke
    Fay, Andre Poisl
    Soares, Andrey
    Pompeo, Antonio Carlos Lima
    Carneiro, Arie
    Kann, Ariel Galapo
    Fogassa, Camilla
    De Freitas Jr, Celso Heitor
    Chade, Daher Cezar
    Herchenhorn, Daniel
    De Almeida, Daniel Vargas Pivato
    Da Rosa, Diogo Augusto Rodrigues
    Wiermann, Evanius Garcia
    Schutz, Fabio Augusto Barros
    Kater, Fabio Roberto
    De Moura, Fernando
    Korkes, Fernando
    Meyer, Fernando
    De Oliveira, Fernando Nunes Galvao
    Sabino, Fernando
    Almeida, Gilberto Laurino
    Avanco, Guilherme
    Guimaraes, Gustavo Cardoso
    Lemos, Gustavo Caserta
    Carvalhal, Gustavo Franco
    Kim, Hanna
    Morbeck, Igor Protzner
    Campagnari, Joao Carlos
    Rinck Jr, Jose Augusto
    Da Ponte, Jose Ricardo Tuma
    Da Trindade, Karine Martins
    Atem, Leonardo
    Borges, Leonardo
    Nogueira, Lucas Mendes
    Batista, Lucas Teixeira e Aguiar
    Maia, Manuel Caitano
    Sadi, Marcus Vinicius
    Rocha, Maria Alzira Almeida
    Luz, Murilo De Almeida
    Smaletz, Oren
    Lages, Paulo Sergio Moraes
    Matuda, Raquel Midori Koga
    Dos Reis, Rodolfo Borges
    Indio, Rodrigo Frota
    Fernandes, Roni De Carvalho
    CLINICAL GENITOURINARY CANCER, 2023, 21 (02) : e58 - e69
  • [38] Dasatinib combined with docetaxel for castration-resistant prostate cancer
    Araujo, John C.
    Mathew, Paul
    Armstrong, Andrew J.
    Braud, Edward L.
    Posadas, Edwin
    Lonberg, Mathew
    Gallick, Gary E.
    Trudel, Geralyn C.
    Paliwal, Prashni
    Agrawal, Shruti
    Logothetis, Christopher J.
    CANCER, 2012, 118 (01) : 63 - 71
  • [39] Molecular biology of castration resistant prostate cancer
    Antonio Medina-Lopez, Rafael
    Taron, Miguel
    Osman-Garcia, Ignacio
    Duran, Ignacio
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (08): : 639 - 650
  • [40] Treatment of Nonmetastatic Castration Resistant Prostate Cancer
    Luo, Jia
    Beer, Tomasz M.
    Graff, Julie N.
    ONCOLOGY-NEW YORK, 2016, 30 (04): : 336 - 344